Abstract: This study aimed to know the opinion of professionals participating in an experiment to implement a pilot for molecular tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae at the Brazilian Unified National Health System (SUS). The detection rate of C. trachomatis and/or N. gonorrhoeae and the factors associated with infection were determined. The strategy included laboratories belonging to the HIV and viral hepatitis viral load network. Testing targeted people who are more vulnerable to sexually transmitted infections and collected urine samples and/or vaginal, endocervical, and/or male urethral swabs. Questionnaires were sent to state managers and laboratory professionals about the implementation of the pilot. Reviews were overall positive. Weaknesses included difficulties changing work processes, lack of human resources, poorly sensitized care professionals, and absence of primary urine tubes, the only input not provided. Strengths included the centralized acquisition of tests, sharing of equipment, and storage of samples at room temperature. Of the 16,177 people who were tested, 1,004 (6.21%) were positive for C. trachomatis; 1,036 (6.4%), for N. gonorrhoeae; and 239 (1.48%), for C. trachomatis/N. gonorrhoeae . Detection of any infection occurred more frequently in young people (≤ 24 vs. > 24 years) (adjOR = 2.65; 95%CI: 2.38-2.96), men (adjOR = 1.95; 95%CI: 1.72-2.21), brown/black individuals (adjOR = 1.06; 95%CI: 1.05-1.11), those in Southeastern Brazil (adjOR = 1.08; 95%CI: 1.02-1.13), and in urethral secretion samples (adjOR = 1.46; 95%CI: 1.41-1.52). Results show the importance of making testing available nationwide, which supported the implementation of a definitive network to detection C. trachomatis/N. gonorrhoeae in SUS.

Resumen: El objetivo de este estudio fue conocer la opinión de los profesionales participantes de la implantación piloto de pruebas moleculares para la detección de Chlamydia trachomatis y Neisseria gonorrhoeae en el Sistema Único de Salud brasileño (SUS). Se determinó la tasa de detección de C. trachomatis y/o N. gonorrhoeae y los factores asociados con la infección. En la estrategia participaron laboratorios pertenecientes a la red de carga viral de VIH y hepatitis virales. La prueba tuvo como público objetivo a personas más vulnerables a las infecciones de transmisión sexual, con recolección de muestras de orina y/o swabs vaginal, endocervicales y/o uretral masculino. Se enviaron cuestionarios a los gestores estatales y a los profesionales de laboratorio sobre la implementación piloto. En general, las evaluaciones fueron positivas. Entre las debilidades, se citó las dificultades en el cambio del proceso de trabajo, la falta de recursos humanos, los profesionales de la asistencia poco sensibilizados y la ausencia del contenedor de orina primaria, el único insumo no suministrado. Como fortalezas, se destaca la adquisición centralizada de pruebas, el intercambio de equipos y el almacenamiento de muestras a temperatura ambiente. De las 16.177 personas evaluadas, 1.004 (6,21%) fueron positivas para C. trachomatis, 1.036 (6,4%) para N. gonorrhoeae y 239 (1,48%) para C. trachomatis/N. gonorrhoeae. La detección de alguna infección ocurrió más en personas jóvenes (≤ 24 vs. > 24 años) (aOR = 2,65; IC95%: 2,38-2,96), del sexo masculino (aOR = 1,95; IC95%: 1,72-2,21), parda/negra (aOR = 1,06; IC95%: 1,05-1,11), localizadas en la región Sudeste (aOR = 1,08; IC95%: 1,02-1,13) y en muestras de secreción uretral (aOR = 1,46; IC95%: 1,41-1,52). Los resultados de este estudio demostraron la importancia de la disponibilidad de la prueba a nivel nacional, los cuales subsidiaron la implantación de la red definitiva para detección de C. trachomatis/N. gonorrhoeae en el SUS.

Resumo: O objetivo deste estudo foi conhecer a opinião dos profissionais participantes da implantação-piloto de testes moleculares para detecção de Chlamydia trachomatis e Neisseria gonorrhoeae no Sistema Único de Saúde (SUS). Determinou-se a taxa de detecção de C. trachomatis e/ou N. gonorrhoeae e os fatores associados à infecção. A estratégia contou com laboratórios pertencentes à rede de carga viral de HIV e hepatites virais. A testagem teve como público-alvo pessoas mais vulnerabilizadas às infecções sexualmente transmissíveis, com coleta de amostras de urina e/ou swabs vaginal, endocervical e/ou uretral masculino. Questionários foram enviados aos gestores estaduais e profissionais de laboratório sobre a implantação-piloto. De maneira geral, as avaliações foram positivas. Entre as fraquezas, citou-se dificuldades na mudança do processo de trabalho, carência de recursos humanos, pouca sensibilidade de profissionais da assistência e ausência de tubo primário de urina, único insumo não fornecido. Como fortaleza, destaca-se aquisição centralizada de testes, compartilhamento de equipamentos e armazenamento de amostras à temperatura ambiente. Das 16.177 pessoas testadas, 1.004 (6,21%) foram positivas para C. trachomatis, 1.036 (6,4%) para N. gonorrhoeae e 239 (1,48%) para C. trachomatis/N. gonorrhoeae. A detecção de infecção ocorreu mais em pessoas jovens (≤ 24 vs. > 24 anos) (aOR = 2,65; IC95%: 2,38-2,96), do sexo masculino (aOR = 1,95; IC95%: 1,72-2,21), pardas/pretas (aOR = 1,06; IC95%: 1,05-1,11), na Região Sudeste (aOR = 1,08; IC95%: 1,02-1,13) e em amostras de secreção uretral (aOR = 1,46; IC95%: 1,41-1,52). Os resultados deste estudo demonstraram a importância da disponibilização da testagem em âmbito nacional, os quais subsidiaram a implantação da rede definitiva para detecção de C. trachomatis/N. gonorrhoeae no SUS.

RESUMO Objetivos O objetivo deste estudo é determinar a prevalência do HPV e de alterações citológicas na população transgênero e contribuir para a criação de políticas públicas. Métodos Estudo descritivo conduzido em ambulatório transgênero em Vitória/ES, entre 2018 e 2021. O dados foram obtidos através de entrevista e informações de prontuário. Coletaram-se amostras anogenitais para a pesquisa de HPV, tricomoníase, gonococo e clamídia, e citologia. Resultados Dos 110 participantes, identificaram-se como homens e mulheres, respectivamente, 60,9% e 34,5%. Encontrou-se prevalência geral de HPV de 58,3%, sendo maior em mulheres (48,1%). Em homens, HPV cervical foi positivo em 38%, e anal em 25%, com alterações citológicas em 9,5%. Mulheres com citologias anais alteradas foram 23,5%. Outras infecções sexualmente transmissíveis: clamídia (4,1%), tricomoníase (12,5%) e nenhum caso de gonorreia. Conclusão O HPV é uma infecção prevalente e com riscos para alterações citológicas na população transgênero, sendo necessários mais estudos de prevalência e de impactos na saúde sexual, para basear políticas de rastreamento e prevenção. públicas VitóriaES Vitória ES Vitória/ES 201 2021 prontuário Coletaramse Coletaram se citologia 11 participantes identificaramse identificaram respectivamente 609 60 9 60,9 345 34 5 34,5% Encontrouse Encontrou 583 58 3 58,3% 48,1%. 481 48,1% . 48 1 (48,1%) 38 38% 25 25% 95 9,5% 235 23 23,5% transmissíveis 4,1%, 41 4,1% , 4 (4,1%) 12,5% 125 12 (12,5% gonorreia sexual prevenção 20 202 6 60, 34,5 58,3 48,1 (48,1% 2 9,5 23,5 4,1 (4,1% 12,5 (12,5 34, 58, 48, (48,1 9, 23, 4, (4,1 12, (12, (48, (4, (12 (48 (4 (1 (

ABSTRACT Objectives The aim of this study was to determine the prevalence of HPV and cytological alterations in the transgender population and contribute to the development of public policies. Methods A descriptive study was conducted in a transgender outpatient clinic in Vitória, Espírito Santo state, between 2018 and 2021. Data were collected through interviews and information from medical records. Anogenital samples were collected for HPV, trichomoniasis, gonococcus and chlamydia testing, cytology. Results Of the 110 participants, 60.9% identified as men and 34.5% as women. The overall prevalence of HPV was 58.3%, being higher in women (48.1%). Among men, cervical HPV was positive in 38%, and anal HPV in 25%, with cytological abnormalities found in 9.5%. Abnormal anal cytology was observed in 23.5% of women. Other sexually transmitted infections: chlamydia (4.1%), trichomoniasis (12.5%) and no cases of gonorrhea. Conclusion HPV is a prevalent infection with risks for cytological abnormalities in the transgender population, and further studies on prevalence and impacts on sexual health are needed to support screening and prevention policies. policies Vitória state 201 2021 records testing 11 participants 609 60 9 60.9 345 34 5 34.5 583 58 3 58.3% 48.1%. 481 48.1% . 48 1 (48.1%) 38 38% 25 25% 95 9.5% 235 23 23.5 infections 4.1%, 41 4.1% , 4 (4.1%) 12.5% 125 12 (12.5% gonorrhea 20 202 6 60. 34. 58.3 48.1 (48.1% 2 9.5 23. 4.1 (4.1% 12.5 (12.5 58. 48. (48.1 9. 4. (4.1 12. (12. (48. (4. (12 (48 (4 (1 (

RESUMEN Objetivos El objetivo de este estudio es determinar la prevalencia del VPH y cambios citológicos en la población transgénero, cooperar a la creación de políticas públicas. Métodos Se realizó estudio descriptivo en un centro especializado en Vitoria-ES entre 2018-2021. Los datos se obtuvieron vía entrevistas y expedientes médicos. Se recogieron muestras anogenitales para investigación de VPH, tricomoniasis, gonorrea, clamidia, y citología. Resultados De 110 participantes, 60,9% y 34,5% se identificaron como hombres y mujeres, respectivamente. Se encontró una prevalencia general de VPH de 58,3%, significativamente mayor en mujeres (48,1%). En hombres, el VPH cervical fue positivo en 38%, el VPH anal en un 25%, con cambios citológicos en 9,5%. Las mujeres con citología anal alterada representaron 23,5%. Otras infecciones de transmision sexual: clamidia (4,1%), tricomoniasis (12,5%), ningún caso de gonorrea. Conclusión VPH es una infección prevalente con riesgos de alteraciones citológicas en esta población. Se necesitan más estudios sobre prevalencia e impactos en la salud sexual para fundamentar políticas de detección y prevención. transgénero públicas VitoriaES Vitoria ES 20182021. 20182021 2018 2021. 2021 2018-2021 médicos gonorrea 11 participantes 609 60 9 60,9 345 34 5 34,5 respectivamente 583 58 3 58,3% 48,1%. 481 48,1% . 48 1 (48,1%) 38 38% 25 25% 95 9,5% 235 23 23,5% 4,1%, 41 4,1% , 4 (4,1%) 12,5%, 125 12,5% 12 (12,5%) prevención 2018202 201 202 2018-202 6 60, 34, 58,3 48,1 (48,1% 2 9,5 23,5 4,1 (4,1% 12,5 (12,5% 201820 20 2018-20 58, 48, (48,1 9, 23, 4, (4,1 12, (12,5 20182 2018-2 (48, (4, (12, 2018- (48 (4 (12 ( (1

Resumo: O objetivo deste estudo foi conhecer a opinião dos profissionais participantes da implantação-piloto de testes moleculares para detecção de Chlamydia trachomatis e Neisseria gonorrhoeae no Sistema Único de Saúde (SUS). Determinou-se a taxa de detecção de C. trachomatis e/ou N. gonorrhoeae e os fatores associados à infecção. A estratégia contou com laboratórios pertencentes à rede de carga viral de HIV e hepatites virais. A testagem teve como público-alvo pessoas mais vulnerabilizadas às infecções sexualmente transmissíveis, com coleta de amostras de urina e/ou swabs vaginal, endocervical e/ou uretral masculino. Questionários foram enviados aos gestores estaduais e profissionais de laboratório sobre a implantação-piloto. De maneira geral, as avaliações foram positivas. Entre as fraquezas, citou-se dificuldades na mudança do processo de trabalho, carência de recursos humanos, pouca sensibilidade de profissionais da assistência e ausência de tubo primário de urina, único insumo não fornecido. Como fortaleza, destaca-se aquisição centralizada de testes, compartilhamento de equipamentos e armazenamento de amostras à temperatura ambiente. Das 16.177 pessoas testadas, 1.004 (6,21%) foram positivas para C. trachomatis, 1.036 (6,4%) para N. gonorrhoeae e 239 (1,48%) para C. trachomatis/N. gonorrhoeae. A detecção de infecção ocorreu mais em pessoas jovens (≤ 24 vs. > 24 anos) (aOR = 2,65; IC95%: 2,38-2,96), do sexo masculino (aOR = 1,95; IC95%: 1,72-2,21), pardas/pretas (aOR = 1,06; IC95%: 1,05-1,11), na Região Sudeste (aOR = 1,08; IC95%: 1,02-1,13) e em amostras de secreção uretral (aOR = 1,46; IC95%: 1,41-1,52). Os resultados deste estudo demonstraram a importância da disponibilização da testagem em âmbito nacional, os quais subsidiaram a implantação da rede definitiva para detecção de C. trachomatis/N. gonorrhoeae no SUS. Resumo implantaçãopiloto piloto SUS . (SUS) Determinouse Determinou se C eou ou N virais públicoalvo público alvo transmissíveis vaginal implantaçãopiloto. piloto. geral fraquezas citouse citou trabalho humanos fornecido fortaleza destacase destaca ambiente 16177 16 177 16.17 testadas 1004 1 004 1.00 6,21% 621 6 21 (6,21% 1036 036 1.03 6,4% 64 4 (6,4% 23 1,48% 148 48 (1,48% trachomatisN trachomatis/N ≤ ( 2 vs anos aOR 2,65 265 65 IC95% IC95 IC 2,382,96, 238296 2,38 2,96 , 38 96 2,38-2,96) 1,95 195 95 1,722,21, 172221 1,72 2,21 72 1,72-2,21) pardaspretas pardas pretas 1,06 106 06 1,051,11, 105111 1,05 1,11 05 11 1,05-1,11) 1,08 108 08 1,021,13 102113 1,02 1,13 02 13 1,02-1,13 1,46 146 46 1,411,52. 141152 1,41 1,52 41 52 1,41-1,52) nacional (SUS 1617 17 16.1 100 00 1.0 6,21 62 (6,21 103 03 6,4 (6,4 1,48 14 (1,48 2,6 26 IC9 382 2,382,96 23829 238 2,3 296 2,9 3 9 2,38-2,96 1,9 19 722 1,722,21 17222 172 1,7 221 2,2 7 1,72-2,21 1,0 10 0 051 1,051,11 10511 105 111 1,1 1,05-1,11 021 1,021,1 10211 102 113 1,02-1,1 1,4 411 1,411,52 14115 141 152 1,5 5 1,41-1,52 161 16. 1. 6,2 (6,2 6, (6, (1,4 2, 2,382,9 2382 29 2,38-2,9 1, 1,722,2 1722 22 1,72-2,2 1,051,1 1051 1,05-1,1 1,021, 1021 1,02-1, 1,411,5 1411 15 1,41-1,5 (6 (1, 2,382, 2,38-2, 1,722, 1,72-2, 1,051, 1,05-1, 1,021 1,02-1 1,411, 1,41-1, (1 2,382 2,38-2 1,722 1,72-2 1,051 1,05-1 1,02- 1,411 1,41-1 2,38- 1,72- 1,05- 1,41-

Abstract: This study aimed to know the opinion of professionals participating in an experiment to implement a pilot for molecular tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae at the Brazilian Unified National Health System (SUS). The detection rate of C. trachomatis and/or N. gonorrhoeae and the factors associated with infection were determined. The strategy included laboratories belonging to the HIV and viral hepatitis viral load network. Testing targeted people who are more vulnerable to sexually transmitted infections and collected urine samples and/or vaginal, endocervical, and/or male urethral swabs. Questionnaires were sent to state managers and laboratory professionals about the implementation of the pilot. Reviews were overall positive. Weaknesses included difficulties changing work processes, lack of human resources, poorly sensitized care professionals, and absence of primary urine tubes, the only input not provided. Strengths included the centralized acquisition of tests, sharing of equipment, and storage of samples at room temperature. Of the 16,177 people who were tested, 1,004 (6.21%) were positive for C. trachomatis; 1,036 (6.4%), for N. gonorrhoeae; and 239 (1.48%), for C. trachomatis/N. gonorrhoeae . Detection of any infection occurred more frequently in young people (≤ 24 vs. > 24 years) (adjOR = 2.65; 95%CI: 2.38-2.96), men (adjOR = 1.95; 95%CI: 1.72-2.21), brown/black individuals (adjOR = 1.06; 95%CI: 1.05-1.11), those in Southeastern Brazil (adjOR = 1.08; 95%CI: 1.02-1.13), and in urethral secretion samples (adjOR = 1.46; 95%CI: 1.41-1.52). Results show the importance of making testing available nationwide, which supported the implementation of a definitive network to detection C. trachomatis/N. gonorrhoeae in SUS. Abstract SUS (SUS) C andor or N determined vaginal endocervical swabs processes resources tubes provided equipment temperature 16177 16 177 16,17 tested 1004 1 004 1,00 6.21% 621 6 21 (6.21% 1036 036 1,03 6.4%, 64 6.4% , 4 (6.4%) 23 1.48%, 148 1.48% 48 (1.48%) trachomatisN trachomatis/N ≤ ( 2 vs years adjOR 2.65 265 65 95%CI 95CI CI 95 2.382.96, 238296 2.38 2.96 38 96 2.38-2.96) 1.95 195 1.722.21, 172221 1.72 2.21 72 1.72-2.21) brownblack brown black 1.06 106 06 1.051.11, 105111 1.05 1.11 05 11 1.05-1.11) 1.08 108 08 1.021.13, 102113 1.02 1.13 02 13 1.02-1.13) 1.46 146 46 1.411.52. 141152 1.41 1.52 41 52 1.41-1.52) nationwide (SUS 1617 17 16,1 100 00 1,0 6.21 62 (6.21 103 03 6.4 (6.4% 14 1.48 (1.48% 2.6 26 9 382 2.382.96 23829 238 2.3 296 2.9 3 2.38-2.96 1.9 19 722 1.722.21 17222 172 1.7 221 2.2 7 1.72-2.21 1.0 10 0 051 1.051.11 10511 105 111 1.1 1.05-1.11 021 1.021.13 10211 102 113 1.02-1.13 1.4 411 1.411.52 14115 141 152 1.5 5 1.41-1.52 161 16, 1, 6.2 (6.2 6. (6.4 (1.48 2. 2.382.9 2382 29 2.38-2.9 1. 1.722.2 1722 22 1.72-2.2 1.051.1 1051 1.05-1.1 1.021.1 1021 1.02-1.1 1.411.5 1411 15 1.41-1.5 (6. (1.4 2.382. 2.38-2. 1.722. 1.72-2. 1.051. 1.05-1. 1.021. 1.02-1. 1.411. 1.41-1. (6 (1. 2.382 2.38-2 1.722 1.72-2 1.051 1.05-1 1.021 1.02-1 1.411 1.41-1 (1 2.38- 1.72- 1.05- 1.02- 1.41-

Resumen: El objetivo de este estudio fue conocer la opinión de los profesionales participantes de la implantación piloto de pruebas moleculares para la detección de Chlamydia trachomatis y Neisseria gonorrhoeae en el Sistema Único de Salud brasileño (SUS). Se determinó la tasa de detección de C. trachomatis y/o N. gonorrhoeae y los factores asociados con la infección. En la estrategia participaron laboratorios pertenecientes a la red de carga viral de VIH y hepatitis virales. La prueba tuvo como público objetivo a personas más vulnerables a las infecciones de transmisión sexual, con recolección de muestras de orina y/o swabs vaginal, endocervicales y/o uretral masculino. Se enviaron cuestionarios a los gestores estatales y a los profesionales de laboratorio sobre la implementación piloto. En general, las evaluaciones fueron positivas. Entre las debilidades, se citó las dificultades en el cambio del proceso de trabajo, la falta de recursos humanos, los profesionales de la asistencia poco sensibilizados y la ausencia del contenedor de orina primaria, el único insumo no suministrado. Como fortalezas, se destaca la adquisición centralizada de pruebas, el intercambio de equipos y el almacenamiento de muestras a temperatura ambiente. De las 16.177 personas evaluadas, 1.004 (6,21%) fueron positivas para C. trachomatis, 1.036 (6,4%) para N. gonorrhoeae y 239 (1,48%) para C. trachomatis/N. gonorrhoeae. La detección de alguna infección ocurrió más en personas jóvenes (≤ 24 vs. > 24 años) (aOR = 2,65; IC95%: 2,38-2,96), del sexo masculino (aOR = 1,95; IC95%: 1,72-2,21), parda/negra (aOR = 1,06; IC95%: 1,05-1,11), localizadas en la región Sudeste (aOR = 1,08; IC95%: 1,02-1,13) y en muestras de secreción uretral (aOR = 1,46; IC95%: 1,41-1,52). Los resultados de este estudio demostraron la importancia de la disponibilidad de la prueba a nivel nacional, los cuales subsidiaron la implantación de la red definitiva para detección de C. trachomatis/N. gonorrhoeae en el SUS. Resumen SUS . (SUS) C yo o N virales sexual vaginal general debilidades trabajo humanos primaria suministrado fortalezas ambiente 16177 16 177 16.17 evaluadas 1004 1 004 1.00 6,21% 621 6 21 (6,21% 1036 036 1.03 6,4% 64 4 (6,4% 23 1,48% 148 48 (1,48% trachomatisN trachomatis/N ≤ ( 2 vs años aOR 2,65 265 65 IC95% IC95 IC 2,382,96, 238296 2,38 2,96 , 38 96 2,38-2,96) 1,95 195 95 1,722,21, 172221 1,72 2,21 72 1,72-2,21) pardanegra parda negra 1,06 106 06 1,051,11, 105111 1,05 1,11 05 11 1,05-1,11) 1,08 108 08 1,021,13 102113 1,02 1,13 02 13 1,02-1,13 1,46 146 46 1,411,52. 141152 1,41 1,52 41 52 1,41-1,52) nacional (SUS 1617 17 16.1 100 00 1.0 6,21 62 (6,21 103 03 6,4 (6,4 1,48 14 (1,48 2,6 26 IC9 382 2,382,96 23829 238 2,3 296 2,9 3 9 2,38-2,96 1,9 19 722 1,722,21 17222 172 1,7 221 2,2 7 1,72-2,21 1,0 10 0 051 1,051,11 10511 105 111 1,1 1,05-1,11 021 1,021,1 10211 102 113 1,02-1,1 1,4 411 1,411,52 14115 141 152 1,5 5 1,41-1,52 161 16. 1. 6,2 (6,2 6, (6, (1,4 2, 2,382,9 2382 29 2,38-2,9 1, 1,722,2 1722 22 1,72-2,2 1,051,1 1051 1,05-1,1 1,021, 1021 1,02-1, 1,411,5 1411 15 1,41-1,5 (6 (1, 2,382, 2,38-2, 1,722, 1,72-2, 1,051, 1,05-1, 1,021 1,02-1 1,411, 1,41-1, (1 2,382 2,38-2 1,722 1,72-2 1,051 1,05-1 1,02- 1,411 1,41-1 2,38- 1,72- 1,05- 1,41-

ABSTRACT The worldwide monkeypox (mpox) outbreak in 2022 showed a high frequency of sexually transmitted infections (STI). A cross-sectional study was carried out using secondary data from the Brazilian official mpox surveillance systems. A total of 10,169 mpox cases were identified, with a median age of 32 years. Among them, 92.3% were male at birth and 57.5% were men who have sex with other men (MSM). Approximately 11% were diagnosed with STI, including 5.8% with syphilis and 2.5% with genital herpes. Individuals aged from 25 to 34 years, MSM, individuals with HIV-positive status, and those manifesting skin eruptions or penile edema were associated with STI. Laboratory investigation for mpox must be implemented as a priority in STI clinics (especially for MSM) to mitigate neglected cases, ensure appropriate treatments, and prevent misdiagnoses. (mpox 202 . (STI) crosssectional cross sectional systems 10169 10 169 10,16 identified 3 years them 923 92 92.3 575 57 5 57.5 MSM. MSM (MSM) 11 58 8 5.8 2 2.5 herpes HIVpositive HIV positive status especially treatments misdiagnoses 20 (STI 1016 1 16 10,1 9 92. 57. (MSM 5. 2. 101 10,

ABSTRACT Objectives The aim of this study was to determine the prevalence of HPV and cytological alterations in the transgender population and contribute to the development of public policies. Methods A descriptive study was conducted in a transgender outpatient clinic in Vitória, Espírito Santo state, between 2018 and 2021. Data were collected through interviews and information from medical records. Anogenital samples were collected for HPV, trichomoniasis, gonococcus and chlamydia testing, cytology. Results Of the 110 participants, 60.9% identified as men and 34.5% as women. The overall prevalence of HPV was 58.3%, being higher in women (48.1%). Among men, cervical HPV was positive in 38%, and anal HPV in 25%, with cytological abnormalities found in 9.5%. Abnormal anal cytology was observed in 23.5% of women. Other sexually transmitted infections: chlamydia (4.1%), trichomoniasis (12.5%) and no cases of gonorrhea. Conclusion HPV is a prevalent infection with risks for cytological abnormalities in the transgender population, and further studies on prevalence and impacts on sexual health are needed to support screening and prevention policies.

RESUMO Objetivos O objetivo deste estudo é determinar a prevalência do HPV e de alterações citológicas na população transgênero e contribuir para a criação de políticas públicas. Métodos Estudo descritivo conduzido em ambulatório transgênero em Vitória/ES, entre 2018 e 2021. O dados foram obtidos através de entrevista e informações de prontuário. Coletaram-se amostras anogenitais para a pesquisa de HPV, tricomoníase, gonococo e clamídia, e citologia. Resultados Dos 110 participantes, identificaram-se como homens e mulheres, respectivamente, 60,9% e 34,5%. Encontrou-se prevalência geral de HPV de 58,3%, sendo maior em mulheres (48,1%). Em homens, HPV cervical foi positivo em 38%, e anal em 25%, com alterações citológicas em 9,5%. Mulheres com citologias anais alteradas foram 23,5%. Outras infecções sexualmente transmissíveis: clamídia (4,1%), tricomoníase (12,5%) e nenhum caso de gonorreia. Conclusão O HPV é uma infecção prevalente e com riscos para alterações citológicas na população transgênero, sendo necessários mais estudos de prevalência e de impactos na saúde sexual, para basear políticas de rastreamento e prevenção.

RESUMEN Objetivos El objetivo de este estudio es determinar la prevalencia del VPH y cambios citológicos en la población transgénero, cooperar a la creación de políticas públicas. Métodos Se realizó estudio descriptivo en un centro especializado en Vitoria-ES entre 2018-2021. Los datos se obtuvieron vía entrevistas y expedientes médicos. Se recogieron muestras anogenitales para investigación de VPH, tricomoniasis, gonorrea, clamidia, y citología. Resultados De 110 participantes, 60,9% y 34,5% se identificaron como hombres y mujeres, respectivamente. Se encontró una prevalencia general de VPH de 58,3%, significativamente mayor en mujeres (48,1%). En hombres, el VPH cervical fue positivo en 38%, el VPH anal en un 25%, con cambios citológicos en 9,5%. Las mujeres con citología anal alterada representaron 23,5%. Otras infecciones de transmision sexual: clamidia (4,1%), tricomoniasis (12,5%), ningún caso de gonorrea. Conclusión VPH es una infección prevalente con riesgos de alteraciones citológicas en esta población. Se necesitan más estudios sobre prevalencia e impactos en la salud sexual para fundamentar políticas de detección y prevención.

ABSTRACT Background: Women living with human immunodeficiency virus (HIV) (WLWH) are more likely to be infected with the oncogenic human papillomavirus (HPV). We assessed the prevalence of high-risk (HR) (16/18/31/33/35/39/45/51/52/56/58/59/68/73/82), probable high-risk (pHR) (26/53/66), and low-risk (LR) (6/11/40/42/43/44/54/61/70) HPV types and their associated risk factors. Methods: This cross-sectional study of WLWH aged 18-64 years included one laboratory and eight HIV-specialty healthcare facilities in the pilot network. Descriptive statistics were used to assess sociodemographic and behavioral characteristics. Adjusted analyses were conducted to evaluate risk factors associated with HR and/or pHR HPV infection in WLWH. Results: From May/2021 to May/2022, 1,914 (92.5%) WLWH participated in the pilot study and had valid HPV-DNA results of self-collected vaginal samples. The median age of the participants was 45 years, 60.1% had ≥ 9 years of schooling, 80.5% were ≤ 18 years at first sexual intercourse, and 51.7% had > 4 sexual partners throughout life. The prevalence of any HPV type, HR HPV, pHR HPV, and LR HPV was 65.8%, 49.6%, 16.7%, and 40.0%, respectively. Age was inversely associated with pHR and/or HR-HPV (p < 0.001), and education level was inversely associated with HR-HPV (p = 0.003) types. Any HR or pHR was associated with being single (p = 0.029) and exchanging sex for drugs (p = 0.037). Conclusions: The prevalence of HPV, especially HR HPV, among WLWH is high in Brazil, highlighting the need for HPV screening in this population. Self-collection of vaginal samples is an important strategy for increasing testing access. Background HIV (HIV (WLWH HPV. . (HPV) highrisk (HR 16/18/31/33/35/39/45/51/52/56/58/59/68/73/82, 161831333539455152565859687382 16/18/31/33/35/39/45/51/52/56/58/59/68/73/82 , 16 31 33 35 39 51 52 56 58 59 68 73 82 (16/18/31/33/35/39/45/51/52/56/58/59/68/73/82) (pHR 26/53/66, 265366 26/53/66 26 53 66 (26/53/66) lowrisk low (LR 6/11/40/42/43/44/54/61/70 61140424344546170 6 11 40 42 43 44 54 61 70 (6/11/40/42/43/44/54/61/70 Methods crosssectional cross sectional 1864 64 18-6 HIVspecialty specialty network characteristics andor Results May2021 May 2021 May/202 May2022 2022 May/2022 1914 1 914 1,91 92.5% 925 92 5 (92.5% HPVDNA DNA selfcollected self collected 601 60 60.1 schooling 805 80 80.5 intercourse 517 7 51.7 life type 658 65 8 65.8% 496 49 49.6% 167 16.7% 400 0 40.0% respectively HRHPV p 0.001, 0001 0.001 001 0.001) 0.003 0003 003 0.029 0029 029 0.037. 0037 0.037 037 0.037) Conclusions Brazil population Selfcollection Self collection access (HPV 16183133353945515256585968738 16/18/31/33/35/39/45/51/52/56/58/59/68/73/8 3 (16/18/31/33/35/39/45/51/52/56/58/59/68/73/82 26536 26/53/6 2 (26/53/66 6/11/40/42/43/44/54/61/7 6114042434454617 (6/11/40/42/43/44/54/61/7 186 18- May202 202 May/20 191 91 1,9 92.5 (92.5 60. 80. 51. 65.8 49.6 16.7 40.0 000 0.00 00 0.02 002 02 0.03 03 1618313335394551525658596873 16/18/31/33/35/39/45/51/52/56/58/59/68/73/ (16/18/31/33/35/39/45/51/52/56/58/59/68/73/8 2653 26/53/ (26/53/6 6/11/40/42/43/44/54/61/ 611404243445461 (6/11/40/42/43/44/54/61/ May20 20 May/2 19 1, 92. (92. 65. 49. 16. 40. 0.0 161831333539455152565859687 16/18/31/33/35/39/45/51/52/56/58/59/68/73 (16/18/31/33/35/39/45/51/52/56/58/59/68/73/ 265 26/53 (26/53/ 6/11/40/42/43/44/54/61 61140424344546 (6/11/40/42/43/44/54/61 May2 May/ (92 0. 16183133353945515256585968 16/18/31/33/35/39/45/51/52/56/58/59/68/7 (16/18/31/33/35/39/45/51/52/56/58/59/68/73 26/5 (26/53 6/11/40/42/43/44/54/6 6114042434454 (6/11/40/42/43/44/54/6 (9 1618313335394551525658596 16/18/31/33/35/39/45/51/52/56/58/59/68/ (16/18/31/33/35/39/45/51/52/56/58/59/68/7 26/ (26/5 6/11/40/42/43/44/54/ 611404243445 (6/11/40/42/43/44/54/ ( 161831333539455152565859 16/18/31/33/35/39/45/51/52/56/58/59/68 (16/18/31/33/35/39/45/51/52/56/58/59/68/ (26/ 6/11/40/42/43/44/54 61140424344 (6/11/40/42/43/44/54 16183133353945515256585 16/18/31/33/35/39/45/51/52/56/58/59/6 (16/18/31/33/35/39/45/51/52/56/58/59/68 (26 6/11/40/42/43/44/5 6114042434 (6/11/40/42/43/44/5 1618313335394551525658 16/18/31/33/35/39/45/51/52/56/58/59/ (16/18/31/33/35/39/45/51/52/56/58/59/6 (2 6/11/40/42/43/44/ 611404243 (6/11/40/42/43/44/ 161831333539455152565 16/18/31/33/35/39/45/51/52/56/58/59 (16/18/31/33/35/39/45/51/52/56/58/59/ 6/11/40/42/43/44 61140424 (6/11/40/42/43/44 16183133353945515256 16/18/31/33/35/39/45/51/52/56/58/5 (16/18/31/33/35/39/45/51/52/56/58/59 6/11/40/42/43/4 6114042 (6/11/40/42/43/4 1618313335394551525 16/18/31/33/35/39/45/51/52/56/58/ (16/18/31/33/35/39/45/51/52/56/58/5 6/11/40/42/43/ 611404 (6/11/40/42/43/ 161831333539455152 16/18/31/33/35/39/45/51/52/56/58 (16/18/31/33/35/39/45/51/52/56/58/ 6/11/40/42/43 61140 (6/11/40/42/43 16183133353945515 16/18/31/33/35/39/45/51/52/56/5 (16/18/31/33/35/39/45/51/52/56/58 6/11/40/42/4 6114 (6/11/40/42/4 1618313335394551 16/18/31/33/35/39/45/51/52/56/ (16/18/31/33/35/39/45/51/52/56/5 6/11/40/42/ 611 (6/11/40/42/ 161831333539455 16/18/31/33/35/39/45/51/52/56 (16/18/31/33/35/39/45/51/52/56/ 6/11/40/42 (6/11/40/42 16183133353945 16/18/31/33/35/39/45/51/52/5 (16/18/31/33/35/39/45/51/52/56 6/11/40/4 (6/11/40/4 1618313335394 16/18/31/33/35/39/45/51/52/ (16/18/31/33/35/39/45/51/52/5 6/11/40/ (6/11/40/ 161831333539 16/18/31/33/35/39/45/51/52 (16/18/31/33/35/39/45/51/52/ 6/11/40 (6/11/40 16183133353 16/18/31/33/35/39/45/51/5 (16/18/31/33/35/39/45/51/52 6/11/4 (6/11/4 1618313335 16/18/31/33/35/39/45/51/ (16/18/31/33/35/39/45/51/5 6/11/ (6/11/ 161831333 16/18/31/33/35/39/45/51 (16/18/31/33/35/39/45/51/ 6/11 (6/11 16183133 16/18/31/33/35/39/45/5 (16/18/31/33/35/39/45/51 6/1 (6/1 1618313 16/18/31/33/35/39/45/ (16/18/31/33/35/39/45/5 6/ (6/ 161831 16/18/31/33/35/39/45 (16/18/31/33/35/39/45/ (6 16183 16/18/31/33/35/39/4 (16/18/31/33/35/39/45 1618 16/18/31/33/35/39/ (16/18/31/33/35/39/4 161 16/18/31/33/35/39 (16/18/31/33/35/39/ 16/18/31/33/35/3 (16/18/31/33/35/39 16/18/31/33/35/ (16/18/31/33/35/3 16/18/31/33/35 (16/18/31/33/35/ 16/18/31/33/3 (16/18/31/33/35 16/18/31/33/ (16/18/31/33/3 16/18/31/33 (16/18/31/33/ 16/18/31/3 (16/18/31/33 16/18/31/ (16/18/31/3 16/18/31 (16/18/31/ 16/18/3 (16/18/31 16/18/ (16/18/3 16/18 (16/18/ 16/1 (16/18 16/ (16/1 (16/ (16 (1

ABSTRACT Background: Gonorrhea is not a notifiable disease in Brazil, and the national health information system does not collect data on reported cases or infection prevalence. Methods: We compiled published data on gonorrhea prevalence in Brazil from cross-sectional surveys and clinical trials between 2000 and 2020. The study entry criteria included a sample size of 50 or more, and Neisseria gonorrhoeae infection detected in urine, urethral, anal, or cervicovaginal specimens using either Nucleic Acid Amplification Test or culture. Gonorrhea prevalence trends between 2000 and 2020 were generated using Spectrum-STI, a statistical trend-fitting model. Results: Forty-five studies with 59 gonorrhea prevalence data points were identified. Fifty data points were for women and represented 21,815 individuals, eight for men encompassing a total of 4,587 individuals, and one for transgender people comprising 345 individuals. The Spectrum-STI estimate for the prevalence of urogenital infection with gonorrhea in women 15-49 in 2020 was 0.63% (95% confidence interval (CI): 0.13-2.23) and was lower than the 1.05% estimated value for 2000 (95% CI: 0.36-2.79). The corresponding figures for men were 0.70% (95% CI: 0.16-2.44) and 1.14% (95% CI: 0.34-3.15). Anal prevalence estimates could not be generated because of insufficient data (three data points). Conclusions: These results suggest that the overall prevalence of genitourinary gonococcal infections in Brazil is less than 1%. Data on gonorrhea prevalence in men and in populations at increased STI vulnerability are limited. Background Methods crosssectional cross sectional 200 5 more urine urethral anal culture 202 SpectrumSTI, SpectrumSTI Spectrum STI, trendfitting trend fitting model Results Fortyfive Forty five identified 21815 21 815 21,81 individuals 4587 4 587 4,58 34 1549 15 49 15-4 063 0 63 0.63 95% 95 (95 CI (CI) 0.132.23 013223 0.13 2.23 13 2 23 0.13-2.23 105 1 05 1.05 0.362.79. 036279 0.36 2.79 . 36 79 0.36-2.79) 070 70 0.70 0.162.44 016244 0.16 2.44 16 44 0.16-2.44 114 14 1.14 0.343.15. 034315 0.34 3.15 3 0.34-3.15) three points. points) Conclusions 1% limited 20 2181 81 21,8 458 58 4,5 154 15- 06 6 0.6 9 (9 (CI 132 0.132.2 01322 013 0.1 223 2.2 0.13-2.2 10 1.0 362 0.362.79 03627 036 0.3 279 2.7 7 0.36-2.79 07 0.7 162 0.162.4 01624 016 244 2.4 0.16-2.4 11 1.1 343 0.343.15 03431 034 315 3.1 0.34-3.15 218 8 21, 45 4, 0. ( 0.132. 0132 01 22 2. 0.13-2. 1. 0.362.7 0362 03 27 0.36-2.7 0.162. 0162 24 0.16-2. 0.343.1 0343 31 3. 0.34-3.1 0.132 0.13-2 0.362. 0.36-2. 0.162 0.16-2 0.343. 0.34-3. 0.13- 0.362 0.36-2 0.16- 0.343 0.34-3 0.36- 0.34-

Resumen Objetivo: describir el proceso de implementación subnacional de la certificación de eliminación de la transmisión vertical (TV) de sífilis y/o VIH, barreras, oportunidades y desafíos. Métodos: en 2022, se evaluaron indicadores del último año completo para la meta de impacto y de los dos últimos años para las de proceso en los sistemas de información; se analizaron informes descriptivos y se reconocieron acciones de cuatro ejes, según las recomendaciones de la OPS/OMS. Resultados: se certificaron 43 municipios ≥ 100.000 mil habitantes, cubriendo 24,6 millones de habitantes; un municipio logró la doble eliminación (VIH-sífilis), 28 la eliminación del VIH y 10 sellos plata; para sífilis, hubo una eliminación, 4 sellos oro, 13 plata y 4 bronce; las regiones Sudeste y Sur obtuvieron más certificaciones. Conclusión: barreras y desafíos fueron superados mediante la colaboración tripartita; la experiencia permitió la integración de la vigilancia con la atención y la cualificación de acciones para la prevención de la TV. Objetivo TV (TV yo o Métodos 2022 información ejes OPSOMS OPS OMS OPS/OMS Resultados 100000 100 000 100.00 habitantes 246 24 6 24, VIHsífilis, VIHsífilis , (VIH-sífilis) 2 1 oro bronce certificaciones Conclusión tripartita 202 10000 00 100.0 (VIH-sífilis 20 1000 0 100.

Resumo Objetivo: descrever o processo de implantação subnacional da certificação da eliminação da transmissão vertical de HIV e/ou sífilis, suas principais barreiras, desafios e oportunidades. Métodos: em 2022, foram avaliados indicadores do último ano completo para meta de impacto, e dos dois últimos anos completos para metas de processo, disponíveis nos sistemas nacionais de informações; foram analisados relatórios descritivos e reconhecidas ações em quatro eixos temáticos, conforme recomendações da OPAS/OMS. Resultados: 43 municípios ≥ 100 mil habitantes foram certificados, abrangendo 24,6 milhões de habitantes; um município alcançou dupla eliminação (HIV-sífilis), 28 alcançaram eliminação para HIV e 10, selos prata; para sífilis, houve uma eliminação, 4 selos ouro, 13 prata e 4 bronze; identificou-se maior número de certificações nas regiões Sudeste e Sul. Conclusão: barreiras e desafios do processo foram superados pela colaboração tripartite; a experiência proporcionou melhor integração da vigilância com a assistência e qualificação das ações para prevenção da transmissão vertical. Objetivo eou ou sífilis oportunidades Métodos 2022 impacto informações temáticos OPASOMS OPAS OMS OPAS/OMS Resultados 10 certificados 246 24 6 24, HIVsífilis, HIVsífilis , (HIV-sífilis) 2 ouro 1 bronze identificouse identificou se Sul Conclusão tripartite 202 (HIV-sífilis 20

Abstract Objective: to describe the subnational implementation process of the certification for elimination of mother-to-child transmission of HIV and/or syphilis, its main barriers, challenges and opportunities. Methods: in 2022, indicators from the last full year for impact targets and the last two full years for process targets, available in national information systems, were evaluated; descriptive reports were analyzed and actions were acknowledged within four thematic axes, according to PAHO/WHO recommendations. Results: 43 municipalities ≥ 100,000 inhabitants were certified, covering 24.6 million inhabitants; one municipality achieved dual elimination (HIV-syphilis), 28 municipalities achieved elimination of HIV and 10 received silver tiers; regarding syphilis, one elimination was observed, along with 4 gold tiers, 13 silver tiers and 4 bronze tiers; a higher number of certifications was identified in the Southeast and South regions. Conclusion: barriers and challenges of the process were overcome through tripartite collaboration; the experience provided better integration of surveillance with care and improved actions aimed at preventing mother-to-child transmission. Objective mothertochild mother child andor or syphilis opportunities Methods 2022 systems evaluated axes PAHOWHO PAHO WHO recommendations Results 100000 100 000 100,00 certified 246 24 6 24. HIVsyphilis, HIVsyphilis , (HIV-syphilis) 2 1 observed regions Conclusion collaboration 202 10000 00 100,0 (HIV-syphilis 20 1000 0 100,

Resumo Objetivo: descrever o processo de implantação subnacional da certificação da eliminação da transmissão vertical de HIV e/ou sífilis, suas principais barreiras, desafios e oportunidades. Métodos: em 2022, foram avaliados indicadores do último ano completo para meta de impacto, e dos dois últimos anos completos para metas de processo, disponíveis nos sistemas nacionais de informações; foram analisados relatórios descritivos e reconhecidas ações em quatro eixos temáticos, conforme recomendações da OPAS/OMS. Resultados: 43 municípios ≥ 100 mil habitantes foram certificados, abrangendo 24,6 milhões de habitantes; um município alcançou dupla eliminação (HIV-sífilis), 28 alcançaram eliminação para HIV e 10, selos prata; para sífilis, houve uma eliminação, 4 selos ouro, 13 prata e 4 bronze; identificou-se maior número de certificações nas regiões Sudeste e Sul. Conclusão: barreiras e desafios do processo foram superados pela colaboração tripartite; a experiência proporcionou melhor integração da vigilância com a assistência e qualificação das ações para prevenção da transmissão vertical.

Resumen Objetivo: describir el proceso de implementación subnacional de la certificación de eliminación de la transmisión vertical (TV) de sífilis y/o VIH, barreras, oportunidades y desafíos. Métodos: en 2022, se evaluaron indicadores del último año completo para la meta de impacto y de los dos últimos años para las de proceso en los sistemas de información; se analizaron informes descriptivos y se reconocieron acciones de cuatro ejes, según las recomendaciones de la OPS/OMS. Resultados: se certificaron 43 municipios ≥ 100.000 mil habitantes, cubriendo 24,6 millones de habitantes; un municipio logró la doble eliminación (VIH-sífilis), 28 la eliminación del VIH y 10 sellos plata; para sífilis, hubo una eliminación, 4 sellos oro, 13 plata y 4 bronce; las regiones Sudeste y Sur obtuvieron más certificaciones. Conclusión: barreras y desafíos fueron superados mediante la colaboración tripartita; la experiencia permitió la integración de la vigilancia con la atención y la cualificación de acciones para la prevención de la TV.

Abstract Objective: to describe the subnational implementation process of the certification for elimination of mother-to-child transmission of HIV and/or syphilis, its main barriers, challenges and opportunities. Methods: in 2022, indicators from the last full year for impact targets and the last two full years for process targets, available in national information systems, were evaluated; descriptive reports were analyzed and actions were acknowledged within four thematic axes, according to PAHO/WHO recommendations. Results: 43 municipalities ≥ 100,000 inhabitants were certified, covering 24.6 million inhabitants; one municipality achieved dual elimination (HIV-syphilis), 28 municipalities achieved elimination of HIV and 10 received silver tiers; regarding syphilis, one elimination was observed, along with 4 gold tiers, 13 silver tiers and 4 bronze tiers; a higher number of certifications was identified in the Southeast and South regions. Conclusion: barriers and challenges of the process were overcome through tripartite collaboration; the experience provided better integration of surveillance with care and improved actions aimed at preventing mother-to-child transmission.